Stock Events

Stock Events

TNF Pharmaceuticals 

$5.2
67
+$1.69+48.15% Wednesday 20:00

Statistics

Day High
8.94
Day Low
4.2
52W High
195
52W Low
3.24
Volume
60,414,025
Avg. Volume
1,818,860
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-27.16MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNFA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap298.84B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap297.32B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Show more...
CEO
Mr. Ian Rhodes CPA
Employees
2
Country
US
ISIN
US62856X2018

Listings

F
DE
DQS.F
XNAS
US
QCLS
BOATS
BOATS
QCLS.BOATS
LSE
GB
0A8D.LSE

0 Comments

Share your thoughts

FAQ

What is TNF Pharmaceuticals stock price today?▼
The current price of TNFA is $5.2 USD — it has increased by +48.15% in the past 24 hours. Watch TNF Pharmaceuticals stock price performance more closely on the chart.
What is TNF Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange TNF Pharmaceuticals stocks are traded under the ticker TNFA.
Is TNF Pharmaceuticals stock price growing?▼
TNFA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year TNF Pharmaceuticals has showed a -80.24% decrease.
What is TNF Pharmaceuticals revenue for the last year?▼
TNF Pharmaceuticals revenue for the last year amounts to 0 USD.
What is TNF Pharmaceuticals net income for the last year?▼
TNFA net income for the last year is -27.16M USD.
How many employees does TNF Pharmaceuticals have?▼
As of April 08, 2026, the company has 2 employees.
In which sector is TNF Pharmaceuticals located?▼
TNF Pharmaceuticals operates in the Health Care sector.
When did TNF Pharmaceuticals complete a stock split?▼
The last stock split for TNF Pharmaceuticals was on September 02, 2025 with a ratio of 1:100.
Where is TNF Pharmaceuticals headquartered?▼
TNF Pharmaceuticals is headquartered in New York, US.